Herombopag Olamine

海曲泊帕乙醇胺

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameHerombopag Olamine
Drug Alias Name海曲泊帕Hetrombopag EthanolamineTrappa ethanolamineHetrombopag olamineHytrapopapa ethanolamine +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionThrombopoietin receptor agonists
TargetsThrombopoietin receptor
Therapy Area/IndicationsThrombocytopeniaPurpura, Thrombocytopenic, IdiopathicAnemia, Aplastic +[8] 
Global Approved IndicationsThrombocytopeniaAnemia, Aplastic
Approved Indications in ChinaThrombocytopeniaAnemia, Aplastic
Original Approved Country/TerritoryMainland China
Original Approved Date2021/06/16
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesFujian Cancer HospitalFudan UniversitySun Yat-Sen University +[5] 
Inactive CompaniesShanghai Hengrui Pharmaceutical Co Ltd
Active IndicationsThrombocytopeniaPurpura, Thrombocytopenic, IdiopathicAnemia, Aplastic +[7] 
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeB02BX
Related LinksN/A